comparemela.com

Latest Breaking News On - Primary immunoglobulin - Page 5 : comparemela.com

Calliditas Therapeutics Submits Supplemental New Drug Application to U S Food and Drug Administration for Full Approval of TARPEYO®

/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a supplemental New Drug.

Exchange commissionDrug administrationNasdaq stockholmNew drug applicationFull prescribingIga nephropathyPrimary immunoglobulinNasdaq global select marketPrivate securities litigation reform actCalliditas therapeuticsWhy targetTreat igaKidney int repNationwide population based cohort

Calliditas Therapeutics Submits Supplemental New Drug Application to U S Food and Drug Administration for Full Approval

STOCKHOLM, June 21, 2023 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX).

Drug administrationExchange commissionNasdaq stockholmNew drug applicationFull prescribingIga nephropathyPrimary immunoglobulinNasdaq global select marketPrivate securities litigation reform actCalliditas therapeuticsWhy targetTreat igaKidney int repNationwide population based cohort

Calliditas Therapeutics: Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study

United kingdomUnited statesRichard philipsonRichard lafayetteKaren molyneuxUniversity of leicesterExchange commissionEuropean renal associationEuropean commissionNasdaq stockholmNeflgard phaseNefigard phasePresentation detailsStanford healthcareKidney inflammationIga nephropathy

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 (1)

STOCKHOLM, May 5, 2023 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX).

United kingdomUnited statesKaren molyneuxRichard lafayetteRichard philipsonEuropean renal associationExchange commissionEuropean commissionUniversity of leicesterNasdaq stockholmNeflgard phaseNefigard phasePresentation detailsStanford healthcareKidney inflammationIga nephropathy

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd.

United kingdomUnited statesKaren molyneuxRichard lafayetteRichard philipsonEuropean renal associationExchange commissionEuropean commissionUniversity of leicesterCalliditas therapeuticsNasdaq stockholmNeflgard phaseNefigard phasePresentation detailsStanford healthcareKidney inflammation

vimarsana © 2020. All Rights Reserved.